National Comprehensive Cancer Network® (NCCN®)

NCCN Cancer Experts Answer Questions about COVID-19 Vaccines

National Comprehensive Cancer Network’s patient information team provides a patient and caregiver version of recently-updated, evidence-based expert consensus recommendations for vaccinating people with cancer against COVID-19.

PLYMOUTH MEETING, PA [June 10, 2021] — The National Comprehensive Cancer Network® (NCCN®) today announced the publication of new guidance on COVID-19 vaccines for people with cancer, intended to clear up confusion for patients and caregivers. The new four-page patient guide is based on the latest expert review of evolving evidence.

“We’re happy to provide plainspoken answers for people with cancer and their loved ones that directly address concerns about the COVID-19 vaccines,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “We know people with cancer are particularly vulnerable to COVID-19, and also that vaccination is a safe way to reduce infection. One of NCCN’s biggest strengths is our ability to quickly bring together leading national experts in order to share their collective knowledge and insights on the evidence in straightforward, non-medical language.”

The newly-published guidance for patients and caregivers covers:

  • A brief overview of all approved vaccines in the United States;
  • Answers to Frequently Asked Questions;
  • The importance, effectiveness, and safety of COVID-19 vaccinations in people with cancer and their caregivers, households, and close contacts;
  • An explanation of which specific types of cancer treatments should appropriately result in a slight delay before vaccination;
  • And the importance of continued mask wearing after vaccination for vulnerable populations.

“We want to reinforce that the decision to get vaccinated against COVID-19 should be something that isn’t scary or confusing for people with cancer,” said Brahm Segal, MD, Roswell Park Comprehensive Cancer Center, Co-Leader of the NCCN COVID-19 Vaccine Advisory Committee. “The members of this NCCN committee have devoted our lives to studying how to reduce infectious diseases and improve outcomes in people with cancer. I personally was happy to get whichever vaccine was first available to me; we want our loved ones, patients, and community at large to have that protection too.”

Visit NCCN.org/patientguidelines to access the COVID-19 patient guide and for additional free, trusted resources that empower people with cancer and their caregivers with unbiased guidance from some of the world’s leading cancer experts.

Updated recommendations on COVID-19 vaccination for oncology care providers

The new patient resource is launching alongside new updates to the NCCN: Cancer and COVID-19 Vaccination recommendations for healthcare providers, which were first published in January. The newly-updated clinician guidance was published at NCCN.org/covid-19 on June 9 and includes emerging information on vaccination in younger people plus discussions around vaccine effectiveness in people with cancer.

The updated clinical recommendations include a note about counseling patients with a history of heparin-induced thrombocytopaenia and/or thrombosis to consider mRNA vaccines instead of the AdV-type 26 vector vaccine. The committee also cautions against antibody testing outside of a study, and encourages more research on the topic of booster shots.

Visit NCCN.org/covid-19 to learn more about how the coronavirus interacts with cancer, including documents, videos, and self-care tips in English, Spanish, and Chinese. Learn why experts agree that recommended cancer screenings are safe and essential, now more than ever.

# # #

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information and follow NCCN on Facebook @NCCNorg, Instagram @NCCNorg, and Twitter @NCCN.

 



Filters close

Showing results

110 of 5872
Released: 24-Jun-2021 4:55 PM EDT
Virus that causes COVID-19 can find alternate route to infect cells
Washington University in St. Louis

The virus that causes COVID-19 normally gets inside cells by attaching to a protein called ACE2. Researchers at Washington University School of Medicine in St. Louis have found that a single mutation confers the ability to enter cells through another route, which may threaten the effectiveness of COVID-19 vaccines and therapeutics designed to block the standard route of entry.

Newswise: Is it a Virus or Bacteria? New Tech Rapidly Tests for COVID-19 and More
Released: 24-Jun-2021 3:05 PM EDT
Is it a Virus or Bacteria? New Tech Rapidly Tests for COVID-19 and More
Homeland Security's Science And Technology Directorate

S&T is preparing for future outbreaks/pandemics by investing in a new tech that can quickly discriminate between bacterial and viral infections so that the U.S. can triage patients and plan a response without delay.

Released: 24-Jun-2021 12:30 PM EDT
A tecnologia de IA e ECG pode descartar rapidamente a infecção por COVID-19, concluiu o estudo da Mayo Clinic
Mayo Clinic

A inteligência artificial (IA) pode oferecer uma maneira de determinar com precisão se uma pessoa não está infectada com a COVID-19. Um estudo retrospectivo internacional descobriu que a infecção pelo SARS-CoV-2, o vírus que causa a COVID-19, cria mudanças elétricas sutis no coração. Um eletrocardiograma (ECG) habilitado com IA pode detectar essas alterações e, potencialmente, ser usado como um teste de triagem rápido e confiável para descartar a infecção por COVID-19.

Released: 24-Jun-2021 12:10 PM EDT
妙佑医疗国际(Mayo Clinic)的研究发现,AI赋能的心电图技术有可能迅速排除COVID-19感染
Mayo Clinic

AI (人工智能)有可能提供准确判断一个人未感染COVID-19(2019冠状病毒病)的方法。一项国际回顾性研究发现,如果感染了导致COVID-19的SARS-CoV-2病毒,患者的心脏会产生微妙的电学变化。AI赋能的心电图(EKG)可以检测到这些变化,并有望被用于进行快速、可靠的COVID-19筛查检测,以排除COVID-19感染。

Newswise: 200421_Felgner_3205_sz-2-768x496.jpg
Released: 24-Jun-2021 11:50 AM EDT
UCI Professor Wins Spain’s Prestigious Princess of Asturias Award for Scientific Research
University of California, Irvine

Irvine, Calif., June 24, 2021 — Philip Felgner, Ph.D., professor in residence of physiology & biophysics at the University of California, Irvine, is one of seven scholars worldwide to win Spain’s prestigious Princess of Asturias Award for Technical and Scientific Research in recognition of their contributions to designing COVID-19 vaccines.

Released: 24-Jun-2021 11:00 AM EDT
New protein engineering method could accelerate the discovery of COVID-19 therapeutics
University of Michigan

Discovering and engineering nanobodies with properties suitable for treating human diseases ranging from cancer to COVID-19 is a time-consuming, laborious process.

Newswise: Decoding humans’ survival from coronaviruses
Released: 24-Jun-2021 11:00 AM EDT
Decoding humans’ survival from coronaviruses
University of Adelaide

An international team of researchers co-led by the University of Adelaide and the University of Arizona has analysed the genomes of more than 2,500 modern humans from 26 worldwide populations, to better understand how humans have adapted to historical coronavirus outbreaks.

access_time Embargo lifts in 2 days
Embargo will expire: 29-Jun-2021 4:00 PM EDT Released to reporters: 24-Jun-2021 10:35 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 29-Jun-2021 4:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: COVIDLockdownSimulations.jpg
Released: 24-Jun-2021 10:00 AM EDT
Pandemic Air Quality Affected By Weather, Not Just Lockdowns
Washington University in St. Louis

Using a diverse set of tools, the lab of Randall Martin shows how the pandemic did – or didn’t – affect levels of particulate matter during COVID lockdowns.

Released: 24-Jun-2021 6:05 AM EDT
Longest known SARS-CoV-2 infection of nearly 300 days successfully treated with new therapy
University of Bristol

An immunocompromised individual with the longest known PCR confirmed case of SARS-CoV-2 infection, lasting more than 290 days, has been successfully treated with two investigational monoclonal antibodies (laboratory engineered antibodies). Clinicians and researchers from the University of Bristol and North Bristol NHS Trust (NBT) worked closely to assess and treat the infection and want to highlight the urgent need for improved access to treatments for such people with persistent SARS-CoV-2 infection.


Showing results

110 of 5872

close
1.60244